31 results
Search Results
2. The integrated care model: facilitating initiation of or transition to home dialysis.
- Author
-
Poinen, Krishna, Mitra, Sandip, and Quinn, Robert R
- Subjects
- *
INTEGRATIVE medicine , *RENAL replacement therapy , *CHRONIC kidney failure , *COVID-19 pandemic , *PATIENT-centered care , *HOME hemodialysis , *HEMODIALYSIS facilities - Abstract
A proportion of end-stage kidney disease (ESKD) patients require kidney replacement therapy to maintain clinical stability. Home dialysis therapies offer convenience, autonomy and potential quality of life improvements, all of which were heightened during the COVID-19 pandemic. While the superiority of specific modalities remains uncertain, patient choice and informed decision-making remain crucial. Missed opportunities for home therapies arise from systemic, programmatic and patient-level barriers. This paper introduces the integrated care model which prioritizes the safe and effective uptake of home therapies while also emphasizing patient-centered care, informed decision-making, and comprehensive support. The integrated care framework addresses challenges in patient identification, assessment, eligibility determination, education and modality transitions. Special considerations for urgent dialysis starts are discussed, acknowledging the unique barriers faced by this population. Continuous quality improvement is emphasized, with the understanding that local challenges may require tailored solutions. Overall, the integrated care model aims to create a seamless and beneficial transition to home dialysis therapies, promoting flexibility and improved quality of life for ESKD patients globally. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Cognitive decline related to chronic kidney disease as an exclusion factor from kidney transplantation: results from an international survey.
- Author
-
Farisco, Michele, Blumblyte, Inga A, Franssen, Casper, Nitsch, Dorothea, Zecchino, Irene, Capasso, Giovambattista, Hafez, Gaye, and Collaborators, COST CONNECT Action
- Subjects
- *
CHRONIC kidney failure , *KIDNEY transplantation , *COGNITION disorders , *PSYCHOSOCIAL factors , *CHRONICALLY ill - Abstract
Background and hypothesis There seems to be a lack of consensus on the necessity and the modality of psychological and specifically cognitive assessment of candidates for kidney transplantation. Both points are often delegated to individual hospitals/centres, whereas international guidelines are inconsistent. We think it is essential to investigate professionals' opinions to advance towards a consistent clinical practice. Methods This paper presents the results of an international survey among clinical professionals, mainly nephrologists from the CONNECT (Cognitive decline in Nephro-Neurology: European Cooperative Target) network and beyond (i.e. from personal contacts of CONNECT members). The survey investigated their opinions about the question of whether cognitive decline in patients with chronic kidney disease may affect their eligibility for kidney transplantation. Results Our results show that most clinicians working with patients affected by chronic kidney disease think that cognitive decline may challenge their eligibility for transplantation despite data that suggest that, in some patients, cognitive problems improve after kidney transplantation. Conclusion We conclude that three needs emerge as particularly pressing: defining agreed-on standards for a multifaceted and multifactorial assessment (i.e. including both clinical/medical and psychosocial factors) of candidates with chronic kidney disease to kidney transplantation; further investigating empirically the causal connection between chronic kidney disease and cognition; and further investigating empirically the possible partial reversibility of cognitive decline after kidney transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. The ERA Registry Annual Report 2021: a summary.
- Author
-
Boerstra, Brittany A, Boenink, Rianne, Astley, Megan E, Bonthuis, Marjolein, ElHafeez, Samar Abd, Monzón, Federico Arribas, Åsberg, Anders, Beckerman, Pazit, Bell, Samira, Amenós, Aleix Cases, Nuez, Pablo Castro de la, Dam, Marc A G J ten, Debska-Slizien, Alicja, Gjorgjievski, Nikola, Giudotti, Rebecca, Helve, Jaakko, Hommel, Kristine, Idrizi, Alma, Indriðason, Ólafur S, and Jarraya, Faiçal
- Subjects
- *
CORPORATION reports , *RENAL replacement therapy , *CHRONIC kidney failure , *KIDNEY transplantation , *PERITONEAL dialysis , *IGA glomerulonephritis - Abstract
Background The European Renal Association (ERA) Registry collects data on kidney replacement therapy (KRT) in patients with end-stage kidney disease (ESKD). This paper is a summary of the ERA Registry Annual Report 2021, including a comparison across treatment modalities. Methods Data was collected from 54 national and regional registries from 36 countries, of which 35 registries from 18 countries contributed individual patient data and 19 registries from 19 countries contributed aggregated data. Using this data, incidence and prevalence of KRT, kidney transplantation rates, survival probabilities and expected remaining lifetimes were calculated. Result In 2021, 533.2 million people in the general population were covered by the ERA Registry. The incidence of KRT was 145 per million population (pmp). In incident patients, 55% were 65 years or older, 64% were male, and the most common primary renal disease (PRD) was diabetes (22%). The prevalence of KRT was 1040 pmp. In prevalent patients, 47% were 65 years or older, 62% were male, and the most common PRDs were diabetes and glomerulonephritis/sclerosis (both 16%). On 31 December 2021, 56% of patients received haemodialysis, 5% received peritoneal dialysis, and 39% were living with a functioning graft. The kidney transplantation rate in 2021 was 37 pmp, a majority coming from deceased donors (66%). For patients initiating KRT between 2012–2016, 5-year survival probability was 52%. Compared to the general population, life expectancy was 65% and 68% shorter for males and females receiving dialysis, and 40% and 43% shorter for males and females living with a functioning graft. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. The ERA Registry Annual Report 2020: a summary.
- Author
-
Astley, Megan E, Boenink, Rianne, ElHafeez, Samar Abd, Trujillo-Alemán, Sara, Arribas, Federico, Åsberg, Anders, Beckerman, Pazit, Bell, Samira, Bouzas-Caamaño, María Encarnación, Farnés, Jordi Comas, Galvão, Ana Amélia, Gjorgjievski, Nikola, Kelmendi, Vjollca Godanci, Guidotti, Rebecca, Helve, Jaakko, Idrizi, Alma, Indriðason, Ólafur S, Ioannou, Kyriakos, Kerschbaum, Julia, and Komissarov, Kirill
- Subjects
- *
CORPORATION reports , *RENAL replacement therapy , *IGA glomerulonephritis , *KIDNEY transplantation , *PERITONEAL dialysis , *HEMODIALYSIS patients - Abstract
Background The European Renal Association (ERA) Registry collects data on kidney replacement therapy (KRT) in patients with ESKD. This paper is a summary of the ERA Registry Annual Report 2020, also including comparisons among primary renal disease (PRD) groups. Methods Data were collected from 52 national and regional registries from 34 European countries and countries bordering the Mediterranean Sea: 35 registries from 18 countries providing individual level data and 17 registries from 17 countries providing aggregated data. Using this data, KRT incidence and prevalence, kidney transplantation rates, expected remaining lifetimes and survival probabilities were calculated. Results A general population of 654.9 million people was covered by the ERA Registry in 2020. The overall incidence of KRT was 128 per million population (p.m.p.). In incident KRT patients, 54% were older than 65 years, 63% were men and the most common PRD was diabetes mellitus (21%). Regarding initial treatment modality in incident patients, 85% received haemodialysis (HD), 11% received peritoneal dialysis (PD) and 4% received a pre-emptive kidney transplant. On 31 December 2020, the prevalence of KRT was 931 p.m.p. In prevalent patients, 45% were older than 65 years, 60% were men and glomerulonephritis was the most common PRD (18%). Of these patients, 58% were on HD, 5% on PD and 37% were living with a kidney transplant. The overall kidney transplantation rate in 2020 was 28 p.m.p. with a majority of kidney grafts from deceased donors (71%). The unadjusted 5-year survival, based on incident dialysis patient from 2011–15, was 41.8%. For patients having received a deceased donor transplant, the unadjusted 5-year survival probability was 86.2% and for patients having received a living donor transplant it was 94.4%. When comparing data by PRD group, differences were found regarding the distribution of age groups, sex and treatment modality received. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. A new series of advanced-level research methods papers.
- Author
-
Jager, Kitty J, Dekker, Friedo W, and Zoccali, Carmine
- Subjects
- *
CONFLICT of interests - Abstract
Hemodialysis, conflict of interest, edetic acid, dialysis procedure, kidney, transplantation, edetate disodium, funding. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
7. Involving patients in treatment decisions, disease management and research for end-stage kidney disease.
- Author
-
Jager, Kitty J and Veer, Sabine N van der
- Subjects
- *
CHRONIC kidney failure , *DISEASE management , *PATIENTS' attitudes , *RENAL replacement therapy , *QUALITY of life - Abstract
Although home therapies treatments may put a substantial burden on patients and their caregivers [[8]], Lambie and Davies [[9]] describe in their paper that absolute contraindications for these are rare. Over recent decades, people have argued for replacing paternalistic methods of managing long-term conditions with models that consider patients to be equal partners in treatment decision-making, disease management, and health service design and research [[1], [3]]. At some point, you run out of resilience, and I've run out. i PATIENT INVOLVEMENT IN DISEASE MANAGEMENT After making a shared treatment decision, patients are encouraged to continue playing an active role in managing their kidney disease, especially if they opted for home dialysis. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
8. Strategies to prevent SARS-CoV-2 transmission in hemodialysis centres across Europe—lessons for the future.
- Author
-
Noordzij, Marlies, Meijers, Björn, Gansevoort, Ron T, Covic, Adrian, Duivenvoorden, Raphaël, Hilbrands, Luuk B, Hemmelder, Marc H, Jager, Kitty J, Mjoen, Geir, Nistor, Ionut, Parshina, Ekaterina, Pessolano, Giuseppina, Tuglular, Serhan, Vart, Priya, Zanoli, Luca, Franssen, Casper F M, and collaborators, ERACODA
- Subjects
- *
SARS-CoV-2 , *COVID-19 pandemic , *COVID-19 , *HAND washing - Abstract
Background Early reports on the pandemic nature of coronavirus disease 2019 (COVID-19) directed the nephrology community to develop infection prevention and control (IPC) guidance. We aimed to make an inventory of strategies that dialysis centres followed to prevent infection with COVID-19 in the first pandemic wave. Methods We analyzed IPC measures taken by hemodialysis centres treating patients presenting with COVID-19 between 1 March 2020 and 31 July 2020 and that completed the European Renal Association COVID-19 Database centre questionnaire. Additionally, we made an inventory of guidelines published in European countries to prevent spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in dialysis centres. Results Data from 73 dialysis units located in and bordering Europe were analyzed. All participating centres implemented IPC measures to mitigate the impact of SARS-CoV-2 during the first pandemic wave. Measures mentioned most often included triage with questions before entering the dialysis ward, measuring body temperature, hand disinfection, masking for all patients and staff, and personal protective equipment for staff members. These measures were also recommended in most of the 14 guidelines that were identified in the inventory of national guidelines and were also scored as being among the most important measures by the authors of this paper. Heterogeneity existed between centres and national guidelines regarding the minimal distance between dialysis chairs and recommendations regarding isolation and cohorting. Conclusions Although variation existed, measures to prevent transmission of SARS-CoV-2 were relatively similar across centres and national guidelines. Further research is needed to assess causal relationships between measures taken and spread of SARS-CoV-2. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Management of fracture risk in CKD—traditional and novel approaches.
- Author
-
Haarhaus, Mathias, Aaltonen, Louise, Cejka, Daniel, Cozzolino, Mario, Jong, Renate T de, D'Haese, Patrick, Evenepoel, Pieter, Lafage-Proust, Marie-Hélène, Mazzaferro, Sandro, McCloskey, Eugene, Salam, Syazrah, Jørgensen, Hanne Skou, and Vervloet, Marc
- Subjects
- *
TREATMENT of fractures , *CHRONIC kidney failure , *VITAMIN D metabolism , *RENAL osteodystrophy , *OSTEOPOROSIS , *PREMATURE aging (Medicine) - Abstract
The coexistence of osteoporosis and chronic kidney disease (CKD) is an evolving healthcare challenge in the face of increasingly aging populations. Globally, accelerating fracture incidence causes disability, impaired quality of life and increased mortality. Consequently, several novel diagnostic and therapeutic tools have been introduced for treatment and prevention of fragility fractures. Despite an especially high fracture risk in CKD, these patients are commonly excluded from interventional trials and clinical guidelines. While management of fracture risk in CKD has been discussed in recent opinion-based reviews and consensus papers in the nephrology literature, many patients with CKD stages 3–5D and osteoporosis are still underdiagnosed and untreated. The current review addresses this potential treatment nihilism by discussing established and novel approaches to diagnosis and prevention of fracture risk in patients with CKD stages 3–5D. Skeletal disorders are common in CKD. A wide variety of underlying pathophysiological processes have been identified, including premature aging, chronic wasting, and disturbances in vitamin D and mineral metabolism, which may impact bone fragility beyond established osteoporosis. We discuss current and emerging concepts of CKD–mineral and bone disorders (CKD-MBD) and integrate management of osteoporosis in CKD with current recommendations for management of CKD-MBD. While many diagnostic and therapeutic approaches to osteoporosis can be applied to patients with CKD, some limitations and caveats need to be considered. Consequently, clinical trials are needed that specifically study fracture prevention strategies in patients with CKD stages 3–5D. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Conducting correlation analysis: important limitations and pitfalls.
- Author
-
Janse, Roemer J, Hoekstra, Tiny, Jager, Kitty J, Zoccali, Carmine, Tripepi, Giovanni, Dekker, Friedo W, and Diepen, Merel van
- Subjects
- *
STATISTICAL correlation , *PEARSON correlation (Statistics) - Abstract
The correlation coefficient is a statistical measure often used in studies to show an association between variables or to look at the agreement between two methods. In this paper, we will discuss not only the basics of the correlation coefficient, such as its assumptions and how it is interpreted, but also important limitations when using the correlation coefficient, such as its assumption of a linear association and its sensitivity to the range of observations. We will also discuss why the coefficient is invalid when used to assess agreement of two methods aiming to measure a certain value, and discuss better alternatives, such as the intraclass coefficient and Bland–Altman's limits of agreement. The concepts discussed in this paper are supported with examples from literature in the field of nephrology. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. relationship between chronic kidney disease–associated pruritus and health-related quality of life: a systematic review.
- Author
-
Poku, Edith, Harnan, Sue, Rooney, Gill, James, Marrissa Martyn-St, Hernández-Alava, Mónica, Schaufler, Thilo, Thokala, Praveen, and Fotheringham, James
- Subjects
- *
QUALITY of life , *CHRONIC kidney failure , *SLEEP interruptions , *ITCHING , *KIDNEYS - Abstract
Background Chronic kidney disease–associated pruritus (CKD-aP) is a common and burdensome condition for end-stage kidney disease (ESKD) patients, especially those receiving haemodialysis. High-quality evidence of the relationship between CKD-aP and health-related quality of life (HRQoL) can therefore inform clinicians and policymakers about treatment choice and reimbursement decisions. Methods A systematic literature review and narrative synthesis stratified by study design and HRQoL instrument was conducted to evaluate in adult ESKD patients receiving in-centre haemodialysis the relationship between CKD-aP and HRQoL assessed using multi dimensional generic or condition-specific preference- or non-preference-based measures. MEDLINE, Embase, Web of Science, BIOSIS Citation Index, Cochrane Library and PsycINFO from inception to March 2020 were searched, with two reviewers extracting data independently. Results Searches identified 2684 unique records, of which 20 papers relating to 18 unique studies [5 randomised controlled trials (RCTs) and 13 observational studies] were included. HRQoL was assessed using four generic and eight disease-specific measures. The impact of CKD-aP was assessed by comparison of means, linear regression and correlation. Observational studies employing comprehensively adjusted multivariable linear regression largely found associations between CKD-aP severities and HRQoL. Analyses suggest this relationship is partially mediated by the sleep disturbance caused by CKD-aP. RCTs showing improvements in CKD-aP severity were associated with clinically meaningful improvements in HRQoL. Compared with generic measures, disease-specific HRQoL instruments reported greater changes with reduced CKD-aP. Heterogeneity in study design and reporting precluded meta-analysis. Conclusions CKD-aP severity was found to be associated with a worsening of HRQoL in the majority of observational and RCT studies. Parallel improvements in CKD-aP and HRQoL with interventions may support their use (PROSPERO registration 175035). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. A new methodological series in CKJ: from basic-level methodology to artificial intelligence in medicine.
- Author
-
Zoccali, Carmine, Stel, Vianda, Dekker, Friedo, and Jager, Kitty J
- Subjects
- *
ARTIFICIAL intelligence , *LANGUAGE models - Abstract
This article discusses the importance of methodological advancements in medical research to improve the accuracy, validity, and relevance of findings. The authors present a series of methodological papers that cover a range of topics, from research design to the integration of artificial intelligence (AI) in medicine. The series includes articles on aetiological and prognostic models, qualitative study design, long-term effects of treatments, biomarkers, decoy receptors, residual risk, and the application of AI in medicine. The authors hope that these articles will serve as a resource for researchers and clinicians, promoting rigorous research design and inspiring further exploration and innovation in the field. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
13. Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study.
- Author
-
Kielstein, Jan T, Heisterkamp, Markus, Jing, Jiaojiao, Nadal, Jennifer, Schmid, Matthias, Kronenberg, Florian, Busch, Martin, Sommerer, Claudia, Lorenzen, Johan M, Eckardt, Kai-Uwe, Köttgen, Anna, and Investigators, for the GCKD Study
- Subjects
- *
CHRONIC kidney failure , *CHRONICALLY ill , *CROSS-sectional method , *EPIDERMAL growth factor receptors , *GLOMERULAR filtration rate - Abstract
Background Despite a plethora of studies on the effect of urate-lowering therapy (ULT) in patients with chronic kidney disease (CKD), current guidelines on the treatment of hyperuricaemia and gout vary, especially concerning the need for dose adjustment of allopurinol, whose main metabolite is accumulating with declining renal function. Data on allopurinol dosing and its relationship to renal function, co-medication and sex and the resulting urate level in large cohorts are missing. Methods We studied a subgroup of 2378 patients of the German Chronic Kidney Disease (GCKD) study to determine prescription patterns of ULT among CKD patients under nephrological care and the relationship of ULT dose to urate levels. Prescription and dosing of ULT were manually abstracted from the patient's paper charts at the baseline visit, in which all currently used medications and their dosing were recorded. Results In this cohort, 39.6% were women, the mean estimated glomerular filtration rate (eGFR) was 51.3 ± 19.3 mL/min/1.73 m2 and the mean age was 59.0 ± 12.4 years. Of the 2378 examined patients, 666 (28.0%) received ULT. The dose of ULT was available for 572 patients. The main ULT agent was allopurinol (94.4%), followed by febuxostat (2.9%) and benzbromarone (2.6%). Of the 540 patients who used allopurinol with a reported daily dose, 480 had an eGFR <60 mL/min/1.73 m2 and 320 had an eGFR <45 mL/min/1.73 m2, 31.5% of the latter (n = 101) received a dose >150 mg/day, the recommended maximal dose for this level of eGFR. The prescribed dose was not related to eGFR: the median eGFR for patients taking 100, 150 and 300 mg/day was 40 [interquartile range (IQR) 32–49], 43 (34–52) and 42 (35–54) mL/min/1.73 m2, respectively. Patients with lower doses of allopurinol had higher serum urate levels than patients with higher (than recommended) allopurinol doses. Sex, alcohol intake, eGFR, use of diuretics and treatment with allopurinol were independent determinants of serum urate levels in multivariate regression analysis. Conclusions The most frequently used drug to lower serum urate levels in this CKD cohort was allopurinol. Even in patients regularly seen by nephrologists, the dose of allopurinol is often not adjusted to the current eGFR. Patients with higher ULT doses achieved better control of their serum urate levels. Lowering of serum urate in CKD patients requires balancing potential adverse effects of allopurinol with suboptimal control of serum urate levels. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Patient-reported outcome measures as a new application in the Swedish Renal Registry: health-related quality of life through RAND-36.
- Author
-
Pagels, Agneta A, Stendahl, Maria, and Evans, Marie
- Subjects
- *
QUALITY of life , *MEDICAL quality control , *VITALITY , *OLDER patients , *CHRONIC kidney failure , *AGE groups - Abstract
Background Although patient-reported outcome measures (PROMs) are gaining increased interest in developing health care quality and are a useful tool in person-centered care, their use in routine care is still limited. The aim of this study is to describe the implementation and initial results of PROMs via the Swedish Renal Registry (SRR) on a national level. Methods After testing and piloting the electronic PROM application, nationwide measures were carried out in 2017 for completing the RAND-36 questionnaire online or by paper in a wide range of chronic kidney disease (CKD) patients (Stages 3–5, dialysis and transplantation) through the SRR. Cross-sectional results during the first year were analyzed by descriptive statistics and stratified by treatment modality. Results A total of 1378 patients from 26 of 68 renal units (39%) completed the questionnaire. The response rate for all participating hemodialysis units was 38.9%. The CKD patients had an impaired health profile compared with a Swedish general population, especially regarding physical functions and assessed general health (GH). Transplanted patients had the highest scores, whereas patients on dialysis treatment had the lowest scores. The youngest age group assessed their physical function higher and experienced fewer physical limitations and less bodily pain than the other age groups but assessed their GH and vitality (VT) relatively low. The oldest age group demonstrated the lowest health profile but rated their mental health higher than the other age groups. The older the patient, the smaller the difference compared with persons of the same age in the general population. Conclusions Nationwide, routine collection of PROMs is feasible in Sweden. However, greater emphasis is needed on motivating clinical staff to embrace the tool and its possibilities in executing person-centered care. CKD patients demonstrate impaired health-related quality of life, especially regarding limitations related to physical problems, GH and VT/energy/fatigue. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. AIN't got no easy answers: recent advances and ongoing controversies around acute interstitial nephritis.
- Author
-
Storrar, Joshua, Woywodt, Alexander, and Arunachalam, Cheralathan
- Subjects
- *
INTERSTITIAL nephritis , *ACUTE kidney failure , *RENAL biopsy , *ANTINEOPLASTIC agents , *BIOMARKERS - Abstract
Acute interstitial nephritis (AIN) is a common cause of acute kidney injury that was first described in 1898. It is most commonly caused by drugs and infections, although other aetiologies are implicated. Here we review two papers published in this issue of Clinical Kidney Journal and provide an update on current advances and controversies relating to AIN. Nussbaum and Perazella describe the diagnostic tools (namely urinary and serum biomarkers) available for AIN and highlight that there is no single test that can accurately predict the diagnosis. As such, renal biopsy remains the gold standard. Wendt et al. present findings from a 20-year retrospective study of biopsy-proven AIN. They found that a high degree of inflammation was associated with a greater chance of renal recovery, in contrast to the presence of cortical scars, which were associated with a worse outcome. There was also a significant number who required renal replacement therapy. They advocate the use of a scoring system for AIN to help direct management. We also discuss new drugs associated with AIN (in particular new anticancer drugs) and unusual forms including granulomatous AIN. Finally, we discuss the opportunities for future research and how this may impact clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. How can we make renal medicine careers more appealing to UK trainees?
- Author
-
Karangizi, Alvin H K, Chanouzas, Dimitrios, Mahdi, Amar, and Foggensteiner, Lukas
- Abstract
Background There is a global decline in interest in careers in renal medicine. This is concerning given the increasing global burden of kidney disease. Previous studies in the USA and Australia have identified factors such as a poor work–life balance, lack of role models and the challenging nature of the speciality as possible reasons behind recruitment struggles. This study aimed to identify factors associated with declining interest among trainees in the UK. Methods We conducted a survey of 150 National Health Service Foundation trainees (interns) and Core Medical Trainees in Health Education West Midlands. Participants completed a 14-part paper-based questionnaire capturing data on trainee demographics, medical school and postgraduate exposure to renal medicine and perceptions of a career in renal medicine. Results There was limited early clinical exposure to renal medicine both in terms of time spent in the speciality and perceived exposure to the range of domains of the speciality. Trainees perceived the speciality as complex with a heavy workload. Very few trainees considered the speciality to be lifestyle oriented. There was also disinterest in taking on the associated general medicine commitments of the training programme. Job experience and identification of role models increased the likelihood of consideration of the speciality. Conclusion This survey has identified key areas to drive interest in the speciality, including early engagement, enthusiastic supervision and increased training flexibility. Urgent attention is required to address these areas and make renal medicine careers more appealing. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease.
- Author
-
Weimbs, Thomas, Shillingford, Jonathan M, Torres, Jacob, Kruger, Samantha L, and Bourgeois, Bryan C
- Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a widespread genetic disease that leads to renal failure in the majority of patients. The very first pharmacological treatment, tolvaptan, received Food and Drug Administration approval in 2018 after previous approval in Europe and other countries. However, tolvaptan is moderately effective and may negatively impact a patient's quality of life due to potentially significant side effects. Additional and improved therapies are still urgently needed, and several clinical trials are underway, which are discussed in the companion paper Müller and Benzing (Management of autosomal-dominant polycystic kidney disease—state-of-the-art) Clin Kidney J 2018; 11 : i2–i13. Here, we discuss new therapeutic avenues that are currently being investigated at the preclinical stage. We focus on mammalian target of rapamycin and dual kinase inhibitors, compounds that target inflammation and histone deacetylases, RNA-targeted therapeutic strategies, glucosylceramide synthase inhibitors, compounds that affect the metabolism of renal cysts and dietary restriction. We discuss tissue targeting to renal cysts of small molecules via the folate receptor, and of monoclonal antibodies via the polymeric immunoglobulin receptor. A general problem with potential pharmacological approaches is that the many molecular targets that have been implicated in ADPKD are all widely expressed and carry out important functions in many organs and tissues. Because ADPKD is a slowly progressing, chronic disease, it is likely that any therapy will have to continue over years and decades. Therefore, systemically distributed drugs are likely to lead to potentially prohibitive extra-renal side effects during extended treatment. Tissue targeting to renal cysts of such drugs is one potential way around this problem. The use of dietary, instead of pharmacological, interventions is another. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. Seasonal variations in the onset of positive and negative renal ANCA-associated vasculitis in Spain.
- Author
-
Draibe, Juliana, Rodó, Xavier, Fulladosa, Xavier, Martínez-Valenzuela, Laura, Diaz-Encarnación, Montserrat, Santos, Lara, Marco, Helena, Quintana, Luis, Rodriguez, Eva, and Barros, Xoana
- Abstract
Background The closure of long-standing gaps in our knowledge of aetiological factors behind anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a major challenge. Descriptive and analytical epidemiological studies can improve our understanding of environmental influences. Reported seasonal variations in AAV, mainly related to Wegener's disease, have shown an increasing number of cases in the winter months, which could be related to an extrinsic factor underlying infection. The objective of this paper was to study seasonal variations in AAV with respect to renal affectation diagnosed in Catalonia, Spain. Methods Two hundred and thirty-four patients diagnosed for renal AAV between 2001 and 2014 in eight hospitals in Catalonia were included in the study. We used medical records to retrospectively analyse the date of the first symptoms attributed to the AAV, ANCA subtypes, the degree of renal impairment and renal histology. Results Of the 234 patients studied, 49.2% were male and 50.8% female. For ANCA status, 8.5% were positive, 15.9% were proteinase-3-positive and 75.6% were myeloperoxidase-positive. In relation to histological classification, 17.8% were sclerotic, 11.7% focal, 38.8% crescentic and 31.7% mixed. Regarding seasonal distribution, we observed a clear seasonal periodicity with a significantly higher incidence of cases in the winter. Applying an Eigen decomposition, we observed a periodic fluctuation of frequencies around the annual cycle with peaks every 10–12 months, and higher incidence of AAV cases in February. Conclusions Our results confirm, in Catalonia, the seasonal periodicity of AAV with a higher incidence in the winter, as formerly described in the literature for other regions. An environmental factor, likely one that is infectious, may explain this finding. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
19. Advocacy for renal replacement therapy: the role of renal registries.
- Author
-
Couchoud, Cecile and Gharbi, Mohamed Benghanem
- Subjects
- *
CHRONIC kidney failure , *RESOURCE allocation , *INTERNISTS , *NEPHROLOGISTS , *INFORMATION storage & retrieval systems - Abstract
The paper by Jardine et al. reporting results from the South African Renal Registry describes a 2-fold success. First, even in a limited-resource environment, survival of patients on renal replacement therapy (RRT) is favourable. Secondly, this information is available because a few years ago, South African nephrologists started a renal registry. These successes cannot conceal, however, that numerous patients are not offered RRT. Robust health information systems make it possible to define chronic kidney disease and end-stage kidney disease (ESKD) burdens, guide resource allocation, inform service planning and enable policy. Registries can highlight inequitable RRT access and help support advocacy in favour of additional resources for ESKD care. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. Heroin crystal nephropathy.
- Author
-
Bautista, Josef Edrik Keith, Merhi, Basma, Gregory, Oliver, Hu, Susie, Henriksen, Kammi, and Gohh, Reginald
- Subjects
- *
KIDNEY diseases , *HEROIN , *HEROIN abuse - Abstract
In this paper we present an interesting case of acute kidney injury and severe metabolic alkalosis in a patient with a history of heavy heroin abuse. Urine microscopy showed numerous broomstick-like crystals. These crystals are also identified in light and electron microscopy. We hypothesize that heroin crystalizes in an alkaline pH, resulting in tubular obstruction and acute kidney injury. Management is mainly supportive as there is no known specific therapy for this condition. This paper highlights the utility of urine microscopy in diagnosing the etiology of acute kidney injury and proposes a novel disease called heroin crystal nephropathy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
21. Landmark Papers in Nephrology.
- Author
-
Ponnusamy, Arvind and Woywodt, Alexander
- Subjects
- *
NEPHROLOGY , *NONFICTION - Abstract
The article reviews the book "Landmark Papers in Nephrology," by John Feehally.
- Published
- 2013
- Full Text
- View/download PDF
22. Incorporating patient-reported symptom assessments into routine care for people with chronic kidney disease.
- Author
-
van der Veer, Sabine N., Aresi, Giovanni, and Gair, Rachel
- Subjects
- *
KIDNEY diseases , *KIDNEY disease treatments , *PATIENTS - Abstract
In this issue of Clinical Kidney Journal, Brown and colleagues show that symptomburden is high across all stages of chronic kidney disease (CKD). Still,management of symptoms in kidney patients leaves roomfor improvement, whichmay partly stem from symptoms being underreported. The use of patient-reported questionnaires may facilitate a more systematic approach to symptomassessment, but to date, themajority of these instruments have been used only in the context of research studies. In this editorial, we review how systematic patient-reported symptom assessments can be incorporated in CKD care. We show examples from an initiative in the UK where 14 renal units explored how to collect and use symptom burden assessments as part of their routine ways of working. We also discuss how tomove from paper-based questionnaires towards digital collection of patient-reported symptomdata. Lastly, we introduce wearable and smartphone sensors as novel methods for collecting information to support and enrich symptomassessments whileminimizing data collection burden [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
23. The role of psychological factors in fatigue among end-stage kidney disease patients: a critical review.
- Author
-
Picariello, Federica, Moss-Morris, Rona, Macdougall, Iain C., and Chilcot, Joseph
- Subjects
- *
CHRONIC kidney failure , *QUALITY of life , *PATIENTS , *PSYCHOLOGY - Abstract
Fatigue is a common and debilitating symptom, affecting 42-89% of end-stage kidney disease patients, persisting even in pre-dialysis care and stable kidney transplantation, with huge repercussions on functioning, quality of life and patient outcomes. This paper presents a critical review of current evidence for the role of psychological factors in renal fatigue. To date, research has concentrated primarily on the contribution of depression, anxiety and subjective sleep quality to the experience of fatigue. These factors display consistent and strong associations with fatigue, above and beyond the role of demographic and clinical factors. Considerably less research is available on other psychological factors, such as social support, stress, self-efficacy, illness and fatigue-specific beliefs and behaviours, and among transplant recipients and patients in pre-dialysis care. Promising evidence is available on the contribution of illness beliefs and behaviours to the experience of fatigue and there is some indication that these factors may vary according to treatment modality, reflecting the differential burdens and coping necessities associated with each treatment modality. However, the use of generic fatigue scales casts doubt on what specifically is being measured among dialysis patients, illness-related fatigue or post-dialysis-specific fatigue. Therefore, it is important to corroborate the available evidence and further explore, qualitatively and quantitatively, the differences in fatigues and fatigue-specific beliefs and behaviours according to renal replacement therapy, to ensure that any model and subsequent intervention is relevant and grounded in the experiences of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
24. Can we routinely measure patient involvement in treatment decision-making in chronic kidney care? A service evaluation in 27 renal units in the UK.
- Author
-
Durand, Marie-Anne, Mooney, Andrew, Thomson, Richard G., Tomson, Charles R. V., Bekker, Hilary L., Casula, Anna, Elias, Robert, Ferraro, Alastair, Lloyd, Amy, van der Veer, Sabine N., and Metcalfe, Wendy
- Subjects
- *
PATIENT participation , *PATIENT decision making , *CHRONIC kidney failure , *PATIENTS - Abstract
Background: Shared decision making is considered an important aspect of chronic disease management. We explored the feasibility of routinely measuring kidney patients' involvement in making decisions about renal replacement therapy (RRT) in National Health Service settings. Methods: We disseminated a 17-item paper questionnaire on involvement in decision-making among adult patients with established kidney failurewho made a decision about RRT in the previous 90 days (Phase 1) and patients who had been receiving RRT for 90-180 days (Phase 2). Recruitment rates were calculated as the ratio between the number of included and expected eligible patients (I : E ratio). We assessed our sample's representativeness by comparing demographics between participants and incident patients in the UK Renal Registry. Results: Three hundred and five (Phase 1) and 187 (Phase 2) patients were included. For Phase 1, the I : E ratio was 0.44 (range, 0.08-2.80) compared with 0.27 (range, 0.04-1.05) in Phase 2. Study participants were more likely to be white compared with incident RRT patients (88 versus 77%; P < 0.0001).We found no difference in age, gender or social deprivation. In Phases 1 and 2, the majority reported a collaborative decision-making style (73 and 69%), and had no decisional conflict (85 and 76%); the median score for shared decision-making experience was 12.5 (Phase 1) and 10 (Phase 2) out of 20. Conclusion: Our study shows the importance of assessing the feasibility of data collection in a chronic disease context prior to implementation in routine practice. Routine measurement of patient involvement in established kidney disease treatment decisions is feasible, but there are challenges in selecting the measure needed to capture experience of involvement, reducing variation in response rate by service and identifying when to capture experience in a service managing people's chronic disease over time. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
25. Pregnancy in end-stage renal disease patients on dialysis: how to achieve a successful delivery.
- Author
-
Manisco, Gianfranco, Potì, Marcello, Maggiulli, Giuseppe, Di Tullio, Massimo, Losappio, Vincenzo, and Vernaglione, Luigi
- Subjects
- *
PREGNANCY , *PRENATAL care , *ABORTION , *KIDNEY diseases , *MEDICAL care - Abstract
Pregnancy in women with chronic kidney disease has always been considered as a challenging event both for the mother and the fetus. Over the years, several improvements have been achieved in the outcome of pregnant chronic renal patients with increasing rates of successful deliveries. To date, evidence suggests that the stage of renal failure is the main predictive factor of worsening residual kidney function and complications in pregnant women. Moreover, the possibility of success of the pregnancy depends on adequate depurative and pharmacological strategies in patients with end-stage renal disease. In this paper, we propose a review of the current literature about this topic presenting our experience as well. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
26. Renal replacement therapy in Latin American end-stage renal disease.
- Author
-
Rosa-Diez, Guillermo, Gonzalez-Bedat, Maria, Pecoits-Filho, Roberto, Marinovich, Sergio, Fernandez, Sdenka, Lugon, Jocemir, Poblete-Badal, Hugo, Elgueta-Miranda, Susana, Gomez, Rafael, Cerdas-Calderon, Manuel, Almaguer-Lopez, Miguel, Freire, Nelly, Leiva-Merino, Ricardo, Rodriguez, Gaspar, Luna-Guerra, Jorge, Bochicchio, Tomasso, Garcia-Garcia, Guillermo, Cano, Nuria, Iron, Norman, and Cuero, Cesar
- Subjects
- *
LATIN Americans , *PRIMORDIALISM , *MEDICAL care , *HEMODIALYSIS , *MALTHUSIANISM - Abstract
The Latin American Dialysis and Renal Transplant Registry (RLADTR) was founded in 1991; it collects data from 20 countries which are members of Sociedad Latinoamericana de Nefrología e Hipertension. This paper presents the results corresponding to the year 2010. This study is an annual survey requesting data on incident and prevalent patients undergoing renal replacement treatment (RRT) in all modalities: hemodialysis (HD), peritoneal dialysis (PD) and living with a functioning graft (LFG), etc. Prevalence and incidence were compared with previous years. The type of renal replacement therapy was analyzed, with special emphasis on PD and transplant (Tx). These variables were correlated with the gross national income (GNI) and the life expectancy at birth. Twenty countries participed in the surveys, covering 99% of the Latin American. The prevalence of end stage renal disease (ESRD) under RRT in Latin America (LA) increased from 119 patients per million population (pmp) in 1991 to 660 pmp in 2010 (HD 413 pmp, PD 135 pmp and LFG 111 pmp). HD proportionally increased more than PD, and Tx HD continues to be the treatment of choice in the region (75%). The kidney Tx rate increased from 3.7 pmp in 1987 to 6.9 pmp in 1991 and to 19.1 in 2010. The total number of Tx's in 2010 was 10 397, with 58% deceased donors. The total RRT prevalence correlated positively with GNI (r2 0.86; P < 0.05) and life expectancy at birth (r2 0.58; P < 0.05). The HD prevalence and the kidney Tx rate correlated significantly with the same indexes, whereas the PD rate showed no correlation with these variables. A tendency to rate stabilization/little growth was reported in the most regional countries. As in previous reports, the global incidence rate correlated significantly only with GNI (r2 0.63; P < 0.05). Diabetes remained the leading cause of ESRD. The most frequent causes of death were cardiovascular (45%) and infections (22%). Neoplasms accounted for 10% of the causes of death. The prevalence of RRT continues to increase, particularly in countries with 100% public health or insurance coverage for RRT, where it approaches rates comparable to those displayed by developed countries with a better GNI. The incidence also continues to increase in both countries that have not yet extended its coverage to 100% of the population as well as in those that have an adequate program for timely detection and treatment of chronic kidney disease (CKD) and its associated risk factors. PD is still an underutilized strategy for RRT in the region. Even though renal Tx is feasible, its growth rate is still not as fast as it should be in order to compensate for the increased prevalence of patients on waiting lists. Diagnostic and prevention programs for hypertension and diabetes, appropriate policies promoting the expansion of PD and organ procurement as well as transplantation as cost-effective forms of RRT are needed in the region. Regional cooperation among Latin American countries, allowing the more developed to guide and train others in starting registries and CKD programs, may be one of the key initiatives to address this deficit. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
27. Oedema, solid organ transplantation and mammalian target of rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs).
- Author
-
Gharbi, Chems, Gueutin, Victor, and Izzedine, Hassan
- Subjects
- *
RAPAMYCIN , *EVEROLIMUS , *EDEMA , *TRANSPLANTATION of organs, tissues, etc. , *CALCINEURIN , *JOINT pain , *HYPERLIPIDEMIA , *DRUG side effects - Abstract
Mammalian target of rapamycin inhibitor (mTOR-I)/proliferation signal inhibitors (PSI) including sirolimus and everolimus represent a new class of drugs increasingly used in solid-organ transplantation as alternatives to calcineurin inhibitors for patients with renal dysfunction, transplant coronary arterial vasculopathy or malignancy. The most frequently occurring mTOR-I/PSI-related adverse events are similar to those associated with other immunosuppressive therapies, but some side effects are more characteristic of proliferation signal inhibitors (e.g. lymphocele, arthralgia, oedema and hyperlipidaemia). The present paper review incidence, clinical presentation and mechanism of oedema within the clinical experience of mTOR-I/PSI in solid organ transplantation. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
28. Nephrogenic hypophosphatemic osteomalacia during adefovir monotherapy for chronic hepatitis B monoinfection.
- Author
-
Yaowen Xu, Pingyan Shen, Xiaoxia Pan, and Nan Chen
- Subjects
- *
OSTEOMALACIA , *BONE diseases , *CHRONIC hepatitis B , *POTASSIUM , *ACIDIFICATION , *CREATININE , *ACIDOSIS , *DRUG side effects , *THERAPEUTICS - Abstract
Background. In this paper, we explore nephrogenic hypophosphatemic osteomalacia associated with low-dose adefovir dipivoxil (ADV) therapy. Methods. Five patients who were treated with ADV for >2 years were included in this study. The metabolic index of phosphate and calcium, renal tubular function, renal function and pathological changes of the patients were investigated. Results. Two male and three female patients were studied. All of the patients presented with a reduced serum phosphate level (0.38-0.60 mmol/L) accompanied with hyperphosphaturia at 10.9-23.8 mmol/24 h. The serum potassium level was also reduced or at lower range (2.56-3.54 mmol/L), but the 24-h urinary potassium was relatively increased. Urinalysis also demonstrated increased excretion of glucose in four patients. Urine protein electrophoresis showed low-to-moderate molecular weight protein. Three patients manifested urine acidification function impairment. Four patients had accompanying renal insufficiency. Three patients had difficulty walking and presented with a reduction in height (2.5-14 cm). Renal biopsy revealed that most of the glomeruli were normal accompanied by mild interstitial fibrosis with inflammatory cell infiltration. ADV treatment was subsequently ceased. Patients were treated with regular phosphate supplementation, citrate acid potassium and calcium bicarbonate. After 6-month treatment, the bone pain was significantly alleviated. Serum creatinine of one patient returned to normal levels and two patients who had difficulty walking were able to walk independently. Conclusions. The current study showed long-term and low-dose ADV treatment in a Chinese population may lead to proximal tubular impairment, metabolic acidosis, hypophosphatemia, hypokalemia, metabolic bone disease, renal osteopathia and renal functional damage. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
29. Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges.
- Author
-
de Geus, Hilde R. H., Betjes, Michiel G., and Bakker, Jan
- Subjects
- *
BIOMARKERS , *ACUTE kidney failure , *DISEASES , *MORTALITY , *CREATININE , *CRITICALLY ill , *SERUM - Abstract
Acute kidney injury (AKI) is strongly associated with increased morbidity and mortality in critically ill patients. Efforts to change its clinical course have failed because clinically available therapeutic measures are currently lacking, and early detection is impossible with serum creatinine (SCr). The demand for earlier markers has prompted the discovery of several candidates to serve this purpose. In this paper, we review available biomarker studies on the early predictive performance in developing AKI in adult critically ill patients. We make an effort to present the results from the perspective of possible clinical utility. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
30. Onconephrology abstracts and publication trends: time to collaborate.
- Author
-
Thakkar, Jyotsana, Wanchoo, Rimda, and Jhaveri, Kenar D.
- Subjects
- *
RENAL cancer , *MEDICAL publishing , *ABSTRACTING - Abstract
Onconephrology is an emerging subspecialty of nephrology. The American Society of Nephrology(ASN) created a forum dedicated to the field of onconephrology in 2011 to improve collaborative care for cancer patients with kidney disease. In this article, we review the ASN Kidney Week abstracts that were related to onconephrology. There has been an increase in the number of onconephrology-related abstracts at ASN over last 3 years. But only one-fifth of abstracts that were onconephrology related in ASN were published in peer review journals. Clinical Kidney Journal (CKJ) has seen an increase in onconephrology publications in the last 3 years. Most were case reports or review articles. The more widespread use of the keyword 'onconephrology' in all such manuscripts may facilitate the search for onconephrology research papers. To advance the field, CKJ has now created an onconephrology subheading for manuscript categorization. We also propose that conference organizers of ASN and other kidney-related society meeting such as International Society of Nephrology, National Kidney Foundation and European Dialysis and Transplantation Association have a separate onconephrology abstract category. Randomized controlled trials in a subspecialty like onconephrology can only be possible when there is collaboration amongst nephrologists and cancer physicians from cancer centers around the world that interact and share research ideas at international meetings. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
31. Timing of cannulation of arteriovenous grafts: are we too cautious?
- Author
-
Shakarchi, Julien Al and Inston, Nicholas
- Subjects
- *
CATHETERIZATION , *THERAPEUTICS , *DIAGNOSIS - Abstract
Background. Timing of first cannulation of an arteriovenous graft has been the subject of great debate for clinicians worldwide. In this paper, we reviewed the current literature on the timing of first cannulation of arteriovenous grafts. Methods. Searches of PubMed, Medline and the Cochrane Library were performed using specific search terms to identify articles, dealing primarily with the timing of dialysis graft cannulation. Results. Following strict inclusion/exclusion criteria by two reviewers, eleven studies were included and divided into subgroups for ePTFE and new generation grafts. Conclusions. The current literature does not seem to support the current guidelines as there is no evidence to suggest that a delay in cannulation of grafts will improve graft survival and patency. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.